Tel Aviv - Delayed Quote ILA

Purple Biotech Ltd (PPBT.TA)

5.90

-0.30

(-4.84%)

At close: January 30 at 5:24:48 PM GMT+2

Purple Biotech Announces Closing of $2.8 Million Registered Direct Offering of American Depositary Shares

REHOVOT, Israel, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or the “Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that overcome tumor immune evasion and drug resistance, today announced the closing of its previously announced registered direct offering of 472,668 of the Company’s American Depositary Shares (“ADSs”), each ADS representing 200 ordinary shares, at a purchase price of $6.00 per ADS. H.C. Wainwright & Co. acte

GlobeNewswire last month

PPBT
-2.98%
Purple Biotech Announces $2.8 Million Registered Direct Offering of American Depositary Shares

REHOVOT, Israel, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or the “Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that overcome tumor immune evasion and drug resistance, today announced that it has entered into a definitive agreement for the purchase and sale of 472,668 of the Company’s American Depositary Shares (“ADSs”), each ADS representing 200 ordinary shares, at a purchase price of $6.00 per ADS, in a registered dir

GlobeNewswire last month

PPBT
-2.98%
Purple Biotech Reports Positive Final Results from Randomized Phase 2 Study of CM24 in Second Line Pancreatic Cancer

Final data demonstrate CM24 in combination with nivolumab and Nal-IRI/5FU/LV chemotherapy clear and consistent improvement across all efficacy endpoints A biomarker enriched patient population analysis based on pretreatment ranges of serum CEACAM1 demonstrated significant improvement in the treatment arm over the control of 79% reduction in risk of death (HR 0.21, P = 0.04) with median OS improvement of 5.1 months and over 90% reduction in risk of progression or death (HR < 0.1, P = 0.003) with

GlobeNewswire last month

PPBT
-2.98%
Purple Biotech Reports Third Quarter 2024 Financial Results

Topline data from Phase 2 CM24 pancreatic cancer trial expected by the end of 2024 New CM24 biomarkers data presented during the third quarter of 2024 including two predicting serum biomarkers identified and associated with CM24 novel targets CAPTN-3 tri-specific antibody platform data presented at the ENA Symposium October 2024 REHOVOT, Israel, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first

GlobeNewswire 2 months ago

PPBT
-2.98%
Purple Biotech Unveils Promising Biomarker for Cancer Therapy

Purple Biotech (PPBT) has released an update. Purple Biotech has identified a new serum biomarker, CEACAM1, which may significantly enhance the efficacy of their oncology therapeutic candidate, CM24, for treating metastatic pancreatic cancer. Patients with certain levels of this biomarker showed a 79% reduction in the risk of death and improved survival rates when treated with CM24 in combination with chemotherapy. As Purple Biotech continues its Phase 2 trials, this discovery could be a game-ch

TipRanks 2 months ago

PPBT
-2.98%
Purple Biotech Identifies Potential New Serum Biomarker for its Lead Oncology Therapeutic Candidate CM24: Associated with 79% Reduction in Risk of Death

Patients with serum CEACAM1 within a defined range prior to treatment demonstrated increased overall survival (OS) and progression free survival (PFS) when treated with CM24 Definition of serum biomarkers for patient selection offers a substantial advantage in developing treatments for cancer CM24, a CEACAM1 inhibitor, is currently being evaluated in a Phase 2 randomized pancreatic cancer study, with topline results expected in Q4 of 2024 REHOVOT, Israel, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Purple

GlobeNewswire 2 months ago

PPBT
-2.98%
Purple Biotech Presents New Data for its Novel Tri-Specific T Cell and NK Cell Engagers Antibody Platform, CAPTN-3, at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

CAPTN-3 demonstrates sustained tumor regression in a triple negative breast cancer in-vivo model; A dose dependent activity and a synergistic effect of the engager arms also seen in non-small cell lung cancer patient-derived explants Lead tribody IM1240 data demonstrated that cytokine release is 5T4-dependent and suppressed by the conditionally activated capping technology, suggesting preferred safety profile Demonstration of additional tribodies suggests CAPTN-3 plug and play platform capabilit

GlobeNewswire 3 months ago

PPBT
-2.98%
Purple Biotech Unveils CAPTN-3 Cancer Therapy

Purple Biotech (PPBT) has released an update. Purple Biotech Ltd., a clinical-stage bio-pharmaceutical company, is set to present its groundbreaking CAPTN-3 platform at the EORTC-NCI-AACR Symposium. The novel CAPTN-3 technology utilizes a tri-specific antibody approach to activate both T cells and NK cells, targeting the 5T4 antigen found in various solid tumors associated with poor clinical outcomes. This innovative therapy aims to enhance anti-tumor efficacy by inducing a strong localized immu

TipRanks 3 months ago

PPBT
-2.98%
Purple Biotech to Present Data for its Tri-Specific Antibody Platform—CAPTN-3—at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

CAPTN-3 is a conditionally activated tri-specific antibody platform that features novel dual engagement of T cells and NK cells to mount an optimal anti-tumoral immune response against cancer REHOVOT, Israel, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that overcome tumor immune evasion and drug resistance, today announced it has been selected for a poster presentation

GlobeNewswire 3 months ago

PPBT
-2.98%
Purple Biotech Reports Additional Positive Interim Data from its Randomized Phase 2 Study with its Lead Oncology Therapeutic Candidate CM24

High CEACAM1 and low PDL1 expression in tumors, as well as their combination identified as potential biomarkers associated with improved overall survival (OS) of pancreatic ductal adenocarcinoma (PDAC) patients (HR=0.1 and prolongation of 4.1 months in median OS, p value 0.01, for the combination), which support the CM24/nivolumab combined treatment.Improved OS is demonstrated for patients with serum neutrophil extracellular trap (NET) marker myeloperoxidase (MPO) (HR=0.38 and prolongation of 3.

GlobeNewswire 4 months ago

PPBT
-2.98%
Upcoming Stock Splits This Week (September 16 to September 20) – Stay Invested

These are the upcoming stock splits for the week of September 16 to September 20, based on TipRanks’ Stock Splits Calendar. A stock split is a corporate action in which the company issues additional common shares to increase the number of outstanding shares. Accordingly, the stock price of the company’s shares decreases, which maintains the market capitalization before and after the split. In contrast, there are also reverse stock splits that reduce the number of outstanding shares (consolidate)

TipRanks 4 months ago

DECK

KSCP

ISPC
Purple Biotech to Present Data for its Lead Oncology Drug CM24 at the AACR Special Conference on Advances in Pancreatic Cancer Research

REHOVOT, Israel, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that overcome tumor immune evasion and drug resistance, today announced it has been selected for a poster presentation at the American Association for Cancer Research® (AACR) Special Conference on Advances in Pancreatic Cancer Research which will be held on September 15-18, 2024, in Boston, Massachusetts. Pur

GlobeNewswire 4 months ago

PPBT
-2.98%
Purple Biotech to Participate at H.C. Wainwright 26th Annual Global Investment Conference

REHOVOT, Israel, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that overcome tumor immune evasion and drug resistance, today announced its executive management will participate in the H.C. Wainwright 26th Annual Global Investment Conference in a Fireside Chat presentation (virtual) and one-on-one meetings. The conference is being held on September 9-11, 2024, and the virt

GlobeNewswire 4 months ago

PPBT
-2.98%
Purple Biotech Reports Second Quarter 2024 Financial Results and Business Highlights

Positive randomized Phase 2 CM24 pancreatic cancer study interim data presented at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting demonstrates improvement in overall survival, progression free survival, objective response rate and all other efficacy endpoints in the combination of CM24+nivolumab and NAL-IRI/5FU/LV chemotherapy cohort Evaluating expansion of CM24 clinical program to a biomarker driven study in additional indications based on CEACAM1 novel oncology target on

GlobeNewswire 5 months ago

PPBT
-2.98%
Purple Biotech Receives Extension to Regain Compliance with the Nasdaq’s Minimum Bid Price Rule

REHOVOT, Israel, July 25, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class oncology therapies that overcome tumor immune evasion and drug resistance, today announced that on July 24, 2024, it received an extension of 180 calendar days from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) to regain compliance with the Nasdaq’s minimum $1.00 bid price requirement s

GlobeNewswire 6 months ago

PPBT
-2.98%
Purple Biotech to Host Virtual KOL Event to Discuss Positive Interim Results from Phase 2 Pancreatic Cancer Study with CM24 on July 11, 2024

REHOVOT, Israel, July 10, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class oncology therapies that overcome tumor immune evasion and drug resistance, today announced further details on its virtual key opinion leader (KOL) event on Thursday, July 11, 2024 at 10:30 AM ET. To register, click here. The event will feature Michael Cecchini, MD (Yale School of Medicine) and E. Gabriela Chiorean, MD,

GlobeNewswire 6 months ago

PPBT
-2.98%
Purple Biotech Announces Closing of Exercise of Warrants for $2 Million Gross Proceeds

REHOVOT, Israel, July 02, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today announced the closing of its previously announced exercise of certain existing warrants to purchase an aggregate of 5,633,509 American Depositary Shares (ADSs), each representing 10 ordinary shares, having original exercise prices ranging fr

GlobeNewswire 6 months ago

PPBT
-2.98%
Purple Biotech Announces Exercise of Warrants for $2 Million Gross Proceeds

REHOVOT, Israel, July 01, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today announced that it has entered into definitive agreements for the exercise of certain existing warrants to purchase an aggregate of 5,633,509 American Depositary Shares (ADSs), each representing 10 ordinary shares, having original exercise pr

GlobeNewswire 6 months ago

PPBT
-2.98%
Purple Biotech Reports Additional Positive Interim Results from its Randomized Phase 2 Pancreatic Cancer Study with CM24 Regarding a Potential Predictive Biomarker for Overall Survival Benefit

New data suggests that baseline serum myeloperoxidase (MPO) levels below the threshold may predict overall survival (OS) improvement when comparing the CM24+nivolumab+Nal-IRI/5FU/LV vs. Nal-IRI/5FU/LV armsData reported at the 2024 ASCO annual meeting demonstrated reduced risk of death and cancer progression, prolongation of OS and progression free survival (PFS) as well as higher objective response rate (ORR) and disease control rate (DCR) and decreasing CA19-9 levels in the CM24+Nivolumab+Nal-I

GlobeNewswire 7 months ago

PPBT
-2.98%
Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic Cancer

26% reduction in risk of death (HR=0.74) and 28% risk reduction in progression or death (HR=0.72) in previously-treated patients administered with CM24+nivolumab+Nal/IRI/5FU/LV vs. standard-of-care(SoC) based on preliminary interim dataProlongation of 2.1 months in median overall survival (OS) and 1.9 months in median progression-free survival (PFS) in the CM24+nivolumab+Nal-IRI/5FU/LV regimen vs. standard-of-careData supported by higher objective response rate (ORR) (25% vs 7%), disease control

GlobeNewswire 7 months ago

PPBT
-2.98%

Performance Overview

Return	PPBT.TA	TA-125
YTD	-20.27%	+4.50%
1-Year	-76.02%	+32.37%
3-Year	-93.23%	+23.74%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Purple Biotech Ltd (PPBT.TA)

Purple Biotech Announces Closing of $2.8 Million Registered Direct Offering of American Depositary Shares

Purple Biotech Announces $2.8 Million Registered Direct Offering of American Depositary Shares

Purple Biotech Reports Positive Final Results from Randomized Phase 2 Study of CM24 in Second Line Pancreatic Cancer

Purple Biotech Reports Third Quarter 2024 Financial Results

Purple Biotech Unveils Promising Biomarker for Cancer Therapy

Purple Biotech Identifies Potential New Serum Biomarker for its Lead Oncology Therapeutic Candidate CM24: Associated with 79% Reduction in Risk of Death

Purple Biotech Presents New Data for its Novel Tri-Specific T Cell and NK Cell Engagers Antibody Platform, CAPTN-3, at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Purple Biotech Unveils CAPTN-3 Cancer Therapy

Purple Biotech to Present Data for its Tri-Specific Antibody Platform—CAPTN-3—at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Purple Biotech Reports Additional Positive Interim Data from its Randomized Phase 2 Study with its Lead Oncology Therapeutic Candidate CM24

Upcoming Stock Splits This Week (September 16 to September 20) – Stay Invested

Purple Biotech to Present Data for its Lead Oncology Drug CM24 at the AACR Special Conference on Advances in Pancreatic Cancer Research

Purple Biotech to Participate at H.C. Wainwright 26th Annual Global Investment Conference

Purple Biotech Reports Second Quarter 2024 Financial Results and Business Highlights

Purple Biotech Receives Extension to Regain Compliance with the Nasdaq’s Minimum Bid Price Rule

Purple Biotech to Host Virtual KOL Event to Discuss Positive Interim Results from Phase 2 Pancreatic Cancer Study with CM24 on July 11, 2024

Purple Biotech Announces Closing of Exercise of Warrants for $2 Million Gross Proceeds

Purple Biotech Announces Exercise of Warrants for $2 Million Gross Proceeds

Purple Biotech Reports Additional Positive Interim Results from its Randomized Phase 2 Pancreatic Cancer Study with CM24 Regarding a Potential Predictive Biomarker for Overall Survival Benefit

Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic Cancer

Performance Overview